SNPHY Stock Santen Pharmaceutical (SNPHY, $9.94) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 11, 2025

GET DAILY SIGNALS

Get AI intraday signals

SNPHY - Santen Pharmaceutical Co., Ltd.

MACD signal

View

Odds of UP Trend

Price: $9.94

Daily change: +$0.26 (+2.63%)

Daily volume: 1.3K

Capitalization: $3.2B

Industry: Pharmaceuticals: Major

This is a Bullish indicator signaling SNPHY's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 53 similar cases where SNPHY's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

SNPHY in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 29, 2025

SNPHY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 37 cases where SNPHY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 65 cases where SNPHY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 12, 2025. You may want to consider a long position or call options on SNPHY as a result. In of 130 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for SNPHY just turned positive on November 11, 2025. Looking at past instances where SNPHY's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SNPHY advanced for three days, in of 231 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day moving average for SNPHY crossed bearishly below the 50-day moving average on October 10, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNPHY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SNPHY entered a downward trend on November 12, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating for company is (best 1 - 100 worst), which means the company is slightly undervalued. The valuation of the company is based on a proprietary formula which takes into account a set of fundamentals and gives us an estimate of the price per share for the company. We then compare this estimate with the current price per share. As a result, this company is rated as undervalued in the industry. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.843) is normal, around the industry mean (9.612). P/E Ratio (16.758) is within average values for comparable stocks, (23.835). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.037). Dividend Yield (0.024) settles around the average of (0.028) among similar stocks. P/S Ratio (1.812) is also within normal values, averaging (3.560).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SNPHY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNPHY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock worse than average.